Compositions and method for treatment of cancer using monoclonal antibody against G.sub.D3 ganglioside together with IL-2
US5104652A · kind A · utility
Assignee
Inventors
Key dates
| Filing date | Jul 5, 1990 |
| Grant date | Apr 14, 1992 |
| Priority date | — |
| Expiry date | Jul 5, 2010 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY10S424/809
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Cell surface gangliosides are presumed to play a role in cell growth and differentiation. Using monoclonal antibodies directed against G.sub.D3, a disialoganglioside expressed predominantly by cells of neuroectodermal origin, we have found that G.sub.D3 is expressed by a subpopulation of cells of the immune system including: a) fetal thymocytes in subcortical regions and near vessels, 2) lymph node lymphocytes in interfollicular areas and near vessels, and 3) a small subset of T cells in the peripheral blood. Mouse monoclonal antibodies (two IgGs, one IgM and F(ab').sub.2 fragments) reacting with G.sub.D3 were found to stimulate proliferation of T cells derived from peripheral blood. Proliferation induced by binding to G.sub.D3 could be augmented by exogenous IL-2, PMA, PHA or Protein A.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.